- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04095052
Food and Alcohol Behavior Study: Meaningful Enhancement (FAB:ME)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Preliminary studies conducted by the investigator's team indicate that 95.7% of previous participants (all alcohol consuming, ages 14-24), were below the threshold for red blood cell (RBC) folate status for women of childbearing potential. Understanding how the interaction of behaviors (alcohol use, nutrient supplementation, diet) contribute to sub-optimal folate status is critical to developing and expanding upon evidence-based FASD prevention programs. Notably, how nutrient supplementation might improve overall folate status in a group with poor folate status and other behaviors that confound the absorption of folate. Because the participants do not view themselves as being at risk for unwanted pregnancy, their motivation to take a supplement for a future pregnancy is very low. This team seeks to collect data on how folate supplementation might improve individually measured outcomes, like cognition and mood, so that interventions might be developed focusing on these individual outcomes.
After becoming aware of the study, prospective participants will undergo a screening questionnaire for inclusion/exclusion criteria. Once the participant meets the inclusion criteria, the study will be fully explained and written informed consent will be handed out. Participants will be randomized in a single-blind manner (participant) in a 1:1 ratio to the Methyl Folate supplement (1,000 mcg, once daily) or placebo (once daily).
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Oklahoma
-
Tulsa, Oklahoma, United States, 74107
- Oklahoma State University Center for Health Sciences
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Females restricted to those living in the United States
- Not currently using hormonal birth control
- Must experience menses
- Must begin the study exactly one week after the start of their menstrual cycle
- Folate consumption must be less than or equal to 250 micrograms of dietary folate equivalents (DFEs)
Exclusion Criteria:
- Current use of a folate supplement
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Methyl Folate
Participants will receive a capsule containing 1,000 mcg methyl folate and microcrystalline cellulose orally once per day for 15 days.
|
1,000 mcg methyl folate and Microcrystalline Cellulose in a capsule
|
Placebo Comparator: Placebo
Participants will receive a microcrystalline cellulose capsule orally once per day for 15 days.
|
Microcrystalline Cellulose capsule
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Red blood cell folate status
Time Frame: Baseline
|
Red blood cell folate status will be analyzed through dried blood spot samples collected on Arrayit blood cards, which use linear flow chromatography to separate whole blood into erythrocyte and serum.
Red blood cell folate values represent a longer-term reduction in folate consumption or increases in folate excretion.
Overturn of red blood cells occurs every 4 months, therefore, red blood cell folate status will only be assessed at baseline.
The WHO-recommended cutoff of <340 nmol/L will be used to assess low red blood cell folate status.
|
Baseline
|
Change in serum folate status
Time Frame: Change from baseline serum folate status at day 1
|
Serum folate values will be analyzed through dried blood spot samples collected on Arrayit blood cards daily, which use linear flow chromatography to separate whole blood into erythrocyte and serum.
The WHO-recommended cutoff of <10 nmol/L will be used to assess low serum folate status.
Results will be reported as a concentration with higher values indicating improved serum folate status.
|
Change from baseline serum folate status at day 1
|
Change in serum folate status
Time Frame: Change from day 1 serum folate status at day 2
|
Serum folate values will be analyzed through dried blood spot samples collected on Arrayit blood cards daily, which use linear flow chromatography to separate whole blood into erythrocyte and serum.
The WHO-recommended cutoff of <10 nmol/L will be used to assess low serum folate status.
Results will be reported as a concentration with higher values indicating improved serum folate status.
|
Change from day 1 serum folate status at day 2
|
Change in serum folate status
Time Frame: Change from day 2 serum folate status at day 3
|
Serum folate values will be analyzed through dried blood spot samples collected on Arrayit blood cards daily, which use linear flow chromatography to separate whole blood into erythrocyte and serum.
The WHO-recommended cutoff of <10 nmol/L will be used to assess low serum folate status.
Results will be reported as a concentration with higher values indicating improved serum folate status.
|
Change from day 2 serum folate status at day 3
|
Change in serum folate status
Time Frame: Change from day 3 serum folate status at day 4
|
Serum folate values will be analyzed through dried blood spot samples collected on Arrayit blood cards daily, which use linear flow chromatography to separate whole blood into erythrocyte and serum.
The WHO-recommended cutoff of <10 nmol/L will be used to assess low serum folate status.
Results will be reported as a concentration with higher values indicating improved serum folate status.
|
Change from day 3 serum folate status at day 4
|
Change in serum folate status
Time Frame: Change from day 4 serum folate status at day 5
|
Serum folate values will be analyzed through dried blood spot samples collected on Arrayit blood cards daily, which use linear flow chromatography to separate whole blood into erythrocyte and serum.
The WHO-recommended cutoff of <10 nmol/L will be used to assess low serum folate status.
Results will be reported as a concentration with higher values indicating improved serum folate status.
|
Change from day 4 serum folate status at day 5
|
Change in serum folate status
Time Frame: Change from day 5 serum folate status at day 6
|
Serum folate values will be analyzed through dried blood spot samples collected on Arrayit blood cards daily, which use linear flow chromatography to separate whole blood into erythrocyte and serum.
The WHO-recommended cutoff of <10 nmol/L will be used to assess low serum folate status.
Results will be reported as a concentration with higher values indicating improved serum folate status.
|
Change from day 5 serum folate status at day 6
|
Change in serum folate status
Time Frame: Change from day 6 serum folate status at day 7
|
Serum folate values will be analyzed through dried blood spot samples collected on Arrayit blood cards daily, which use linear flow chromatography to separate whole blood into erythrocyte and serum.
The WHO-recommended cutoff of <10 nmol/L will be used to assess low serum folate status.
Results will be reported as a concentration with higher values indicating improved serum folate status.
|
Change from day 6 serum folate status at day 7
|
Change in serum folate status
Time Frame: Change from day 7 serum folate status at day 8
|
Serum folate values will be analyzed through dried blood spot samples collected on Arrayit blood cards daily, which use linear flow chromatography to separate whole blood into erythrocyte and serum.
The WHO-recommended cutoff of <10 nmol/L will be used to assess low serum folate status.
Results will be reported as a concentration with higher values indicating improved serum folate status.
|
Change from day 7 serum folate status at day 8
|
Change in serum folate status
Time Frame: Change from day 8 serum folate status at day 9
|
Serum folate values will be analyzed through dried blood spot samples collected on Arrayit blood cards daily, which use linear flow chromatography to separate whole blood into erythrocyte and serum.
The WHO-recommended cutoff of <10 nmol/L will be used to assess low serum folate status.
Results will be reported as a concentration with higher values indicating improved serum folate status.
|
Change from day 8 serum folate status at day 9
|
Change in serum folate status
Time Frame: Change from day 9 serum folate status at day 10
|
Serum folate values will be analyzed through dried blood spot samples collected on Arrayit blood cards daily, which use linear flow chromatography to separate whole blood into erythrocyte and serum.
The WHO-recommended cutoff of <10 nmol/L will be used to assess low serum folate status.
Results will be reported as a concentration with higher values indicating improved serum folate status.
|
Change from day 9 serum folate status at day 10
|
Change in serum folate status
Time Frame: Change from day 10 serum folate status at day 11
|
Serum folate values will be analyzed through dried blood spot samples collected on Arrayit blood cards daily, which use linear flow chromatography to separate whole blood into erythrocyte and serum.
The WHO-recommended cutoff of <10 nmol/L will be used to assess low serum folate status.
Results will be reported as a concentration with higher values indicating improved serum folate status.
|
Change from day 10 serum folate status at day 11
|
Change in serum folate status
Time Frame: Change from day 11 serum folate status at day 12
|
Serum folate values will be analyzed through dried blood spot samples collected on Arrayit blood cards daily, which use linear flow chromatography to separate whole blood into erythrocyte and serum.
The WHO-recommended cutoff of <10 nmol/L will be used to assess low serum folate status.
Results will be reported as a concentration with higher values indicating improved serum folate status.
|
Change from day 11 serum folate status at day 12
|
Change in serum folate status
Time Frame: Change from day 12 serum folate status at day 13
|
Serum folate values will be analyzed through dried blood spot samples collected on Arrayit blood cards daily, which use linear flow chromatography to separate whole blood into erythrocyte and serum.
The WHO-recommended cutoff of <10 nmol/L will be used to assess low serum folate status.
Results will be reported as a concentration with higher values indicating improved serum folate status.
|
Change from day 12 serum folate status at day 13
|
Change in serum folate status
Time Frame: Change from day 13 serum folate status at day 14
|
Serum folate values will be analyzed through dried blood spot samples collected on Arrayit blood cards daily, which use linear flow chromatography to separate whole blood into erythrocyte and serum.
The WHO-recommended cutoff of <10 nmol/L will be used to assess low serum folate status.
Results will be reported as a concentration with higher values indicating improved serum folate status.
|
Change from day 13 serum folate status at day 14
|
Change in serum folate status
Time Frame: Change from day 14 serum folate status at day 15
|
Serum folate values will be analyzed through dried blood spot samples collected on Arrayit blood cards daily, which use linear flow chromatography to separate whole blood into erythrocyte and serum.
The WHO-recommended cutoff of <10 nmol/L will be used to assess low serum folate status.
Results will be reported as a concentration with higher values indicating improved serum folate status.
|
Change from day 14 serum folate status at day 15
|
Change in gastrointestinal symptoms
Time Frame: Change from baseline gastrointestinal health status at day 7
|
Gastrointestinal health symptoms will be assessed by a short questionnaire aimed at capturing side-effects commonly associated with oral supplementation such as nausea, vomiting, heartburn, abdominal pain, diarrhea, and constipation.
|
Change from baseline gastrointestinal health status at day 7
|
Change in gastrointestinal symptoms
Time Frame: Change from day 7 gastrointestinal health status at day 15
|
Gastrointestinal health symptoms will be assessed by a short questionnaire aimed at capturing side-effects commonly associated with oral supplementation such as nausea, vomiting, heartburn, abdominal pain, diarrhea, and constipation.
|
Change from day 7 gastrointestinal health status at day 15
|
Change in dietary folate consumption
Time Frame: Change from baseline dietary folate consumption at day 7
|
The Block Dietary Folate Equivalents (DFE) Screener: A 21-item measure validated specifically for folate.
This screener measures folate intake within a 1-week time period and will be assessed throughout the study period.
DFE results are given as an calculated average of micro-grams per day.
DFE's above 400 micro-grams meet the RDA for the study population.
|
Change from baseline dietary folate consumption at day 7
|
Change in dietary folate consumption
Time Frame: Change from day 7 dietary folate consumption at day 15
|
The Block Dietary Folate Equivalents (DFE) Screener: A 21-item measure validated specifically for folate.
This screener measures folate intake within a 1-week time period and will be assessed throughout the study period.
DFE results are given as an calculated average of micro-grams per day.
DFE's above 400 micro-grams meet the RDA for the study population.
|
Change from day 7 dietary folate consumption at day 15
|
Change in mood
Time Frame: Change from baseline mood at day 7
|
The Patient Health Questionnaire (PHQ-9): 9-item self-report screening tool used to assess and identify symptoms related to depression. The PHQ-9 has potential scores of 0-27 with scores of 5, 10, 15, and 20 representing thresholds for mild, moderate, moderately severe, and severe depression, respectively. Positive and Negative Affect Schedule (PANAS-SF): 20-item self-report screening tool used to assess both positive and negative affect. Scores can range from 10-50, with higher scores representing higher levels of positive affect. Scores can range from 10-50, with lower scores representing lower levels of negative affect. Brief Mood Introspection Scale (BMIS): 16-adjective scale to assess pleasant-unpleasant mood (scale range of 16-64), arousal-calm mood (scale range of 12-48), positive-tired mood (scale range of 7-28), and negative-relaxed mood (scale range of 6-24). Adding up the scored items reveals where an individual lies on each of the 4 subscales. |
Change from baseline mood at day 7
|
Change in mood
Time Frame: Change from day 7 mood at day 15
|
The Patient Health Questionnaire (PHQ-9): 9-item self-report screening tool used to assess and identify symptoms related to depression. The PHQ-9 has potential scores of 0-27 with scores of 5, 10, 15, and 20 representing thresholds for mild, moderate, moderately severe, and severe depression, respectively. Positive and Negative Affect Schedule (PANAS-SF): 20-item self-report screening tool used to assess both positive and negative affect. Scores can range from 10-50, with higher scores representing higher levels of positive affect. Scores can range from 10-50, with lower scores representing lower levels of negative affect. Brief Mood Introspection Scale (BMIS): 16-adjective scale to assess pleasant-unpleasant mood (scale range of 16-64), arousal-calm mood (scale range of 12-48), positive-tired mood (scale range of 7-28), and negative-relaxed mood (scale range of 6-24). Adding up the scored items reveals where an individual lies on each of the 4 subscales. |
Change from day 7 mood at day 15
|
Change in cognition
Time Frame: Change from baseline cognitive functioning at day 7
|
The NIH Toolbox Cognition Battery assesses cognitive functioning.
Cognitive reports include several calculated scores including Age-Corrected Standard Scores, Uncorrected Standard Scores, and Fully Corrected T-Scores.
The higher the score on each cognitive test, the higher the cognitive functioning.
|
Change from baseline cognitive functioning at day 7
|
Change in cognition
Time Frame: Change from day 7 cognitive functioning at day 15
|
The NIH Toolbox Cognition Battery assesses cognitive functioning.
Cognitive reports include several calculated scores including Age-Corrected Standard Scores, Uncorrected Standard Scores, and Fully Corrected T-Scores.
The higher the score on each cognitive test, the higher the cognitive functioning.
|
Change from day 7 cognitive functioning at day 15
|
Change in sleep patterns
Time Frame: Change from baseline sleep patterns at day 7
|
The Oura Ring is a wellness tracker used to track an individual's nightly sleep cycle and physical activity 24 hours per day.
All data is synced via a smartphone application.
|
Change from baseline sleep patterns at day 7
|
Change in sleep patterns
Time Frame: Change from day 7 sleep patterns at day 15
|
The Oura Ring is a wellness tracker used to track an individual's nightly sleep cycle and physical activity 24 hours per day.
All data is synced via a smartphone application.
|
Change from day 7 sleep patterns at day 15
|
Change in hair, nails, and skin satisfaction
Time Frame: Change from baseline hair, nails, and skin satisfaction at day 7
|
A 6 item self-report screening tool for assessing satisfaction of hair, nails, and skin.
Scores can range from 0-6.
Results are recorded using a likert scale and will indicate changes in physical attribute satisfaction as supplementation occurs.
A higher score represents a greater satisfaction whereas a lower score represents a lower satisfaction.
|
Change from baseline hair, nails, and skin satisfaction at day 7
|
Change in hair, nails, and skin satisfaction
Time Frame: Change from day 7 hair, nails, and skin satisfaction at day 15
|
A 6 item self-report screening tool for assessing satisfaction of hair, nails, and skin.
Scores can range from 0-6.
Results are recorded using a likert scale and will indicate changes in physical attribute satisfaction as supplementation occurs.
A higher score represents a greater satisfaction whereas a lower score represents a lower satisfaction.
|
Change from day 7 hair, nails, and skin satisfaction at day 15
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2022001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Folate Deficiency
-
University Medical Centre LjubljanaRecruitingBody Weight | IVF | Nutrient Deficiency | Dietary Vitamin B12 Deficiency Anemia | Dietary Folate Deficiency AnemiaSlovenia
-
National Institute of Health and NutritionCompletedFolate Deficiency
-
The Hospital for Sick ChildrenNatural Sciences and Engineering Research Council, CanadaActive, not recruiting
-
University of California, DavisUniversity of California, San Francisco; Ethiopian Public Health Institute; Nutrition...Enrolling by invitationFolate Deficiency | Iodine Deficiency | Anemia, Macrocytic | Anemia Deficiency | Salt IntakeEthiopia
-
University of California, DavisUniversity of California, San Francisco; University of Rhode Island; Ethiopian... and other collaboratorsNot yet recruitingVitamin B 12 Deficiency | Folate Deficiency | Iodine Deficiency | Anemia Deficiency | Salt Intake | Anemia Macrocytic
-
Cornell UniversityCenters for Disease Control and Prevention; Arogyavaram Medical CentreActive, not recruitingAnemia | Vitamin B 12 Deficiency | Folate DeficiencyIndia
-
Wageningen Centre for Food SciencesWageningen UniversityCompletedHealthy | Folate BioavailabilityNetherlands
-
Cornell UniversityCenters for Disease Control and Prevention; St. John's Research Institute; Arogyavaram...Active, not recruiting
-
Medical University of ViennaCompletedObesity, Morbid | Bariatric Surgery Candidate | Vitamin B 12 Deficiency | Folate Deficiency | Homocystine; Metabolic DisorderAustria
-
University of British ColumbiaCompleted
Clinical Trials on Methyl Folate
-
Alexandria UniversityActive, not recruitingEnd Stage Renal Disease | Hypertension, RenalEgypt
-
Massachusetts General HospitalNational Alliance for Research on Schizophrenia and DepressionCompleted
-
Reata, a wholly owned subsidiary of BiogenCompleted
-
Reata, a wholly owned subsidiary of BiogenCompleted
-
Reata, a wholly owned subsidiary of BiogenWithdrawnDiabetes Mellitus, Type 2 | Renal Insufficiency, Chronic
-
Reata, a wholly owned subsidiary of BiogenCompletedHealthy | Hepatic ImpairmentUnited States
-
Federal University of ParaíbaCompletedOverweight and Obesity
-
Mansoura UniversitySwedish University of Agricultural Sciences; The Swedish Research Council for...Completed
-
Universidade Estadual de LondrinaCompletedCardiovascular Disease | Hemodialysis | Chronic Renal Failure | Uremia | HyperhomocysteinemiaBrazil
-
University of PennsylvaniaCompletedResectable Breast CancerUnited States